In the News

In an effort to put patients at the center, pharmaceutical companies are starting to gather input from patients earlier in the clinical trial process.

PPD sets terms of planned initial public offering.

PPD announces the pricing of its initial public offering of 60 million shares of its common stock at $27.00 per share.

Shares of PPD’s common stock begin trading on The Nasdaq Global Select Market under the symbol “PPD.”

Alistair Davidson, Guoliang Liu and Bill Wang assess how the clinical trial market has responded over the past few years and analyze the future of the China market.

PPD announces the launch of its initial public offering of 60 million shares of its common stock.

PPD is expanding its operations and leadership team in China to provide enhanced clinical development, laboratory, regulatory, site conduct, patient access and post-approval services for international and China-based biopharmaceutical companies.

The initial public offering price is expected to be between $24.00 and $27.00 per share.

PPD has applied to have its common stock approved for listing on The Nasdaq Global Select Market under the symbol “PPD.”